{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:26:37Z","timestamp":1780471597768,"version":"3.54.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anti-tumor necrosis factor (TNF) drugs have improved the prognosis for juvenile idiopathic arthritis (JIA) significantly. However, evidence for individual treatment decisions based on serum anti-TNF drug levels and the presence of anti-drug antibodies (ADAbs) in children is scarce. We aimed to assess if anti-TNF drug levels and\/or ADAbs influenced physician\u2019s treatment decisions in children with JIA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients\u2019 records in our center were retrospectively screened for measurements of anti-TNF drug levels and ADAbs in children with JIA using etanercept, adalimumab or infliximab. Clinical characteristics and disease activity were retrieved from patient charts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We analyzed 142 measurements of anti-TNF drug levels in 65 children with JIA. Of these, ninety-seven (68.3%) were trough concentrations. <jats:italic>N<\/jats:italic>\u2009=\u200914\/97 (14.4%) of these showed trough concentrations within the therapeutic drug range known for adults with RA and IBD. ADAbs against adalimumab were detected in seven patients and against infliximab in one patient. Seven (87,5%) of these ADAb-positive patients had non-detectable drug levels. A flowchart was made on decisions including rational dose escalation, stopping treatment in the presence of ADAbs and undetectable drug levels, showing that 45% of measurements influenced treatment decisions, which concerned 65% of patients (<jats:italic>n<\/jats:italic>\u2009=\u200942\/65).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In the majority of patients, measurement of anti-TNF drug levels led to changes in treatment. A wide variation of anti-TNF drug levels was found possibly due to differences in drug clearance in different age groups. There is need for determination of therapeutic drug ranges and pharmacokinetic curves for anti-TNF and other biologics in children with JIA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12969-021-00545-x","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:03:07Z","timestamp":1619690587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic drug monitoring of anti-TNF drugs: an overview of applicability in daily clinical practice in the era of treatment with biologics in juvenile idiopathic arthritis (JIA)"],"prefix":"10.1186","volume":"19","author":[{"given":"A.","family":"Nassar-Sheikh Rashid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schonenberg-Meinema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. C.","family":"Bergkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bakhlakh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"issue":"6","key":"545_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40272-016-0186-0","volume":"18","author":"S Blazina","year":"2016","unstructured":"Blazina S, Markelj G, Avramovic MZ, Toplak N, Avcin T. Management of Juvenile Idiopathic Arthritis: a clinical guide. Paediatr Drugs. 2016;18(6):397\u2013412. https:\/\/doi.org\/10.1007\/s40272-016-0186-0.","journal-title":"Paediatr Drugs"},{"issue":"10","key":"545_CR2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.3899\/jrheum.130133","volume":"40","author":"A Tambralli","year":"2013","unstructured":"Tambralli A, Beukelman T, Weiser P, Atkinson TP, Cron RQ, Stoll ML. High doses of infliximab in the management of juvenile idiopathic arthritis. J Rheumatol. 2013;40(10):1749\u201355. https:\/\/doi.org\/10.3899\/jrheum.130133.","journal-title":"J Rheumatol"},{"issue":"2","key":"545_CR3","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/rheumatology\/ker378","volume":"51","author":"L Haverman","year":"2012","unstructured":"Haverman L, Verhoof EJ, Maurice-Stam H, Heymans HS, Gerlag DM, van Rossum MA, et al. Health-related quality of life and psychosocial developmental trajectory in young female beneficiaries with JIA. Rheumatology (Oxford). 2012;51(2):368\u201374. https:\/\/doi.org\/10.1093\/rheumatology\/ker378.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"545_CR4","doi-asserted-by":"publisher","first-page":"e000304","DOI":"10.1136\/rmdopen-2016-000304","volume":"2","author":"F Oliveira-Ramos","year":"2016","unstructured":"Oliveira-Ramos F, Eusebio M, Martins FM, Mourao AF, Furtado C, Campanilho-Marques R, et al. Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damage. RMD Open. 2016;2(2):e000304.","journal-title":"RMD Open"},{"issue":"5","key":"545_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1136\/adc.2009.170860","volume":"94","author":"MW Beresford","year":"2009","unstructured":"Beresford MW, Baildam EM. New advances in the management of juvenile idiopathic arthritis--2: the era of biologicals. Arch Dis Child Educ Pract Ed. 2009;94(5):151\u20136. https:\/\/doi.org\/10.1136\/adc.2009.170860.","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"6","key":"545_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","volume":"77","author":"A Ravelli","year":"2018","unstructured":"Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819\u201328. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213030.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"545_CR7","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/annrheumdis-2013-204172","volume":"74","author":"MF Pouw","year":"2015","unstructured":"Pouw MF, Krieckaert CL, Nurmohamed MT, van der Kleij D, Aarden L, Rispens T, et al. Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis. 2015;74(3):513\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204172.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"545_CR8","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/03009742.2018.1433232","volume":"47","author":"F Siljehult","year":"2018","unstructured":"Siljehult F, Arlestig L, Eriksson C, Rantapaa-Dahlqvist S. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. Scand J Rheumatol. 2018;47(5):345\u201350. https:\/\/doi.org\/10.1080\/03009742.2018.1433232.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"545_CR9","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1136\/ard.2004.030452","volume":"64","author":"GJ Wolbink","year":"2005","unstructured":"Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64(5):704\u20137. https:\/\/doi.org\/10.1136\/ard.2004.030452.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"545_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1203\/PDR.0b013e318208451d","volume":"69","author":"M Kosmac","year":"2011","unstructured":"Kosmac M, Avcin T, Toplak N, Simonini G, Cimaz R, Curin SV. Exploring the binding sites of anti-infliximab antibodies in pediatric patients with rheumatic diseases treated with infliximab. Pediatr Res. 2011;69(3):243\u20138. https:\/\/doi.org\/10.1203\/PDR.0b013e318208451d.","journal-title":"Pediatr Res"},{"issue":"10","key":"545_CR11","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/rheumatology\/kez030","volume":"58","author":"MJH Doeleman","year":"2019","unstructured":"Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839\u201349. https:\/\/doi.org\/10.1093\/rheumatology\/kez030.","journal-title":"Rheumatology (Oxford)"},{"key":"545_CR12","unstructured":"Infliximab: Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remicade-epar-product-information_en.pdf. Accessed 4 June 2019."},{"issue":"2","key":"545_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/rheumatology\/kev277","volume":"55","author":"T Schaeverbeke","year":"2016","unstructured":"Schaeverbeke T, Truchetet ME, Kostine M, Barnetche T, Bannwarth B, Richez C. Immunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practice. Rheumatology (Oxford). 2016;55(2):210\u201320. https:\/\/doi.org\/10.1093\/rheumatology\/kev277.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"545_CR14","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007;56(9):3096\u2013106. https:\/\/doi.org\/10.1002\/art.22838.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"545_CR15","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41(9):1552\u201363. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W.","journal-title":"Arthritis Rheum"},{"key":"545_CR16","doi-asserted-by":"publisher","unstructured":"Carrascosa Carrilllo JM, Toro Montecinos M, Ballesca Lopez F, Teniente Serra A, Martinez Caceres E, Ferrandiz C. Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. J Dermatolog Treat. 2018;29(2):140\u20134. https:\/\/doi.org\/10.1080\/09546634.2017.1341619. Epub 2017 Jul 6. PMID: 28604127.","DOI":"10.1080\/09546634.2017.1341619"},{"issue":"4","key":"545_CR17","first-page":"B4616","volume":"60","author":"C Steenholdt","year":"2013","unstructured":"Steenholdt C. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn\u2019s disease. Dan Med J. 2013;60(4):B4616.","journal-title":"Dan Med J"},{"issue":"9","key":"545_CR18","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/00365521.2015.1027264","volume":"50","author":"DR Hoekman","year":"2015","unstructured":"Hoekman DR, Brandse JF, de Meij TG, Hummel TZ, Lowenberg M, Benninga MA, et al. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2015;50(9):1110\u20137. https:\/\/doi.org\/10.3109\/00365521.2015.1027264.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"545_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MPG.0000000000002112","volume":"68","author":"S Naviglio","year":"2019","unstructured":"Naviglio S, Lacorte D, Lucafo M, Cifu A, Favretto D, Cuzzoni E, et al. Causes of treatment failure in children with inflammatory bowel disease treated with infliximab: a pharmacokinetic study. J Pediatr Gastroenterol Nutr. 2019;68(1):37\u201344. https:\/\/doi.org\/10.1097\/MPG.0000000000002112.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"545_CR20","first-page":"3","volume-title":"Applied Pharmacology","author":"K Stan","year":"2011","unstructured":"Stan K, Bardal JEW, Martin DS. Applied Pharmacology; 2011. p. 3\u201316."},{"issue":"4","key":"545_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","volume":"7","author":"K Papamichael","year":"2016","unstructured":"Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Front Gastroenterol. 2016;7(4):289\u2013300. https:\/\/doi.org\/10.1136\/flgastro-2016-100685.","journal-title":"Front Gastroenterol"},{"issue":"4","key":"545_CR22","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/FTD.0000000000000423","volume":"39","author":"S Murias","year":"2017","unstructured":"Murias S, Magallares L, Albizuri F, Pascual-Salcedo D, Dreesen E, Mulleman D. Current practices for therapeutic drug monitoring of biopharmaceuticals in pediatrics. Ther Drug Monit. 2017;39(4):370\u20138. https:\/\/doi.org\/10.1097\/FTD.0000000000000423.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"545_CR23","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","volume":"74","author":"EL Kneepkens","year":"2015","unstructured":"Kneepkens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, et al. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis. 2015;74(10):1825\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205213.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"545_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","volume":"71","author":"A Jamnitski","year":"2012","unstructured":"Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis. 2012;71(1):88\u201391. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200184.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"545_CR25","first-page":"48","volume":"11","author":"N Singh","year":"2015","unstructured":"Singh N, Dubinsky MC. Therapeutic drug monitoring in children and young adults with inflammatory bowel disease: a practical approach. Gastroenterol Hepatol (N Y). 2015;11(1):48\u201355.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"545_CR26","unstructured":"Personalized Medicine 2020 and beyond \u2013 Preparing Europe for leading the global way (PerMed)."},{"issue":"4","key":"545_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2017-211781","volume":"77","author":"MJ l'Ami","year":"2018","unstructured":"l'Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, et al. Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. 2018;77(4):484\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211781.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"545_CR28","first-page":"390","volume":"31","author":"RE Petty","year":"2004","unstructured":"Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31(2):390\u20132.","journal-title":"J Rheumatol"},{"issue":"8","key":"545_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/apt.12030","volume":"36","author":"N Vande Casteele","year":"2012","unstructured":"Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36(8):765\u201371. https:\/\/doi.org\/10.1111\/apt.12030.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"545_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1002\/art.21671","volume":"54","author":"GJ Wolbink","year":"2006","unstructured":"Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(3):711\u20135. https:\/\/doi.org\/10.1002\/art.21671.","journal-title":"Arthritis Rheum"},{"issue":"1\u20132","key":"545_CR31","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jim.2011.09.011","volume":"375","author":"T Rispens","year":"2012","unstructured":"Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012;375(1\u20132):93\u20139. https:\/\/doi.org\/10.1016\/j.jim.2011.09.011.","journal-title":"J Immunol Methods"},{"issue":"3","key":"545_CR32","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","volume":"21","author":"GJ Wolbink","year":"2009","unstructured":"Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol. 2009;21(3):211\u20135. https:\/\/doi.org\/10.1097\/BOR.0b013e328329ed8b.","journal-title":"Curr Opin Rheumatol"},{"key":"545_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2020.00312","volume":"11","author":"S Atiqi","year":"2020","unstructured":"Atiqi S, Hooijberg F, Loeff FC, Rispens T, Wolbink GJ. Immunogenicity of TNF-inhibitors. Front Immunol. 2020;11:312. https:\/\/doi.org\/10.3389\/fimmu.2020.00312.","journal-title":"Front Immunol"},{"key":"545_CR34","doi-asserted-by":"publisher","first-page":"765380","DOI":"10.5402\/2012\/765380","volume":"2012","author":"S Sukumaran","year":"2012","unstructured":"Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol. 2012;2012:765380.","journal-title":"ISRN Rheumatol"},{"issue":"3","key":"545_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395\u2013404. https:\/\/doi.org\/10.1111\/bcp.12267.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"545_CR36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol. 2018;14(6):585\u201399. https:\/\/doi.org\/10.1080\/17425255.2018.1482278.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"545_CR37","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84(5):548\u201358. https:\/\/doi.org\/10.1038\/clpt.2008.170.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"545_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1586\/17512433.2016.1133288","volume":"9","author":"AS Strik","year":"2016","unstructured":"Strik AS, Bots SJ, D'Haens G, Lowenberg M. Optimization of anti-TNF therapy in patients with inflammatory bowel disease. Expert Rev Clin Pharmacol. 2016;9(3):429\u201339. https:\/\/doi.org\/10.1586\/17512433.2016.1133288.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"545_CR39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/ket260.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"545_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015;29(4):241\u201358. https:\/\/doi.org\/10.1007\/s40259-015-0134-5.","journal-title":"BioDrugs"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00545-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00545-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00545-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T10:16:33Z","timestamp":1619691393000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00545-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["545"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00545-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"26 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Medical Research Involving Human Subjects Act (WMO) does not apply to this study and an official approval of this study was not required by the committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TR reports grants and personal fees from Genmab, outside the submitted work.All the other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}